Kadmon Holdings Llc (KDMN) Stock Price, Forecast & Analysis
USA - NASDAQ:KDMN -
KDMN Key Statistics, Chart & Performance
The current stock price of KDMN is 9.5 null. In the past month the price increased by 5.67%. In the past year, price increased by 174.57%.
KDMN Latest News, Press Relases and Analysis
KDMN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About KDMN
Company Profile
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company is headquartered in New York City, New York. The company went IPO on 2016-07-27. The firm's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The company is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The firm has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.
Company Info
Kadmon Holdings Llc
450 E 29th St
New York City NEW YORK 10016 US
CEO: Harlan W. Waksal
Employees: 0
Phone: 18339005366.0
Kadmon Holdings Llc / KDMN FAQ
What does Kadmon Holdings Llc do?
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company is headquartered in New York City, New York. The company went IPO on 2016-07-27. The firm's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The company is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The firm has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.
What is the stock price of Kadmon Holdings Llc today?
The current stock price of KDMN is 9.5 null. The price increased by 0.21% in the last trading session.
Does Kadmon Holdings Llc pay dividends?
KDMN does not pay a dividend.
What is the ChartMill rating of Kadmon Holdings Llc stock?
KDMN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is Kadmon Holdings Llc (KDMN) expected to grow?
The Revenue of Kadmon Holdings Llc (KDMN) is expected to decline by -3.81% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of KDMN stock?
Kadmon Holdings Llc (KDMN) has a market capitalization of 1.63B null. This makes KDMN a Small Cap stock.
Can you provide the ownership details for KDMN stock?
You can find the ownership structure of Kadmon Holdings Llc (KDMN) on the Ownership tab.
KDMN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KDMN. When comparing the yearly performance of all stocks, KDMN is one of the better performing stocks in the market, outperforming 97.65% of all stocks.
KDMN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KDMN. KDMN may be in some trouble as it scores bad on both profitability and health.
KDMN Financial Highlights
Over the last trailing twelve months KDMN reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS increased by 28.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -5955.81% | ||
| ROA | -35.84% | ||
| ROE | N/A | ||
| Debt/Equity | 6.96 |
KDMN Forecast & Estimates
12 analysts have analysed KDMN and the average price target is 12.34 null. This implies a price increase of 29.92% is expected in the next year compared to the current price of 9.5.
For the next year, analysts expect an EPS growth of -11.43% and a revenue growth -3.81% for KDMN